Incredible” results from the PATINA trial suggested a new standard of care for HER2, ER-positive metastatic breast cancer.

First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...

The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...

A phase 3 trial reveals that combining brentuximab vedotin with lenalidomide and rituximab improves survival in relapsed ...

Scientists have made a discovery which could lead to the first change in standard liver cancer treatment in 20 years. Two ...

The results of this first phase 2 study of belzutifan combined with cabozantinib suggest that dual targeting of HIF-2α and VEGF pathways might be an effective first-line treatment strategy in advanced ...

Veliparib plus temozolomide did not significantly extend overall survival in patients with newly diagnosed, ...

Martin Dreyling, MD, discusses how the safety and efficacy results from the TRIANGLE study in mantle cell lymphoma differ from prior expectations.

The objective response rate was 78.6% in the overall cohort, 76.9% in patients with a PD-L1 combined positive score (CPS) below 1, 68.8% in patients with a PD-L1 CPS of 1-9, and 100% in patients with ...

Now, China-based CARsgen has shared pivotal results from the latter portion of a phase 1/2 study evaluating the therapy for ...

The FDA cleared the investigational new drug application for REC-4539, allowing for the start of a phase 1/2 trial in small ...

The FDA approved inavolisib for triplet combination use for treatment of PIK3CA-mutated locally advanced or metastatic ...